Tuesday, April 09, 2024 10:37:52 AM
Bio of Dr. Mitchell Glass (from https://www.medproinvestors.com/team; out of date probably)
Dr. Mitchell Glass is a 25 year veteran of the pharmaceutical industry.
His experience includes senior positions at top ten pharmaceutical companies,
as well as investment in and management of start-ups and biotechs.
After seven years of research, teaching and patient care at the University of Pennsylvania, Dr. Glass joined ICI Pharmaceuticals in 1988 where he established the pulmonary therapeutics group and led the development and submission of the antileukotriene ACCOLATE®. From 1995 to 1996, Dr. Glass was Vice President and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, including submission of the NDA/MAA for COREG®. From 1998 to 2003, Dr. Glass was Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics Inc. (AGIX), where he led product development from IND to initiation of Phase 3 for AGI1067 and was a member of the IPO team. Dr. Glass later joined AQUMEN Biopharmaceuticals KK and NA as CEO of AQUMEN NA and currently serves as Executive VP R&D and Chief Medical Officer of Invion Limited. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.
***
I have no idea what any of this 8-K signifies. Maybe tells us some preferred stock can be converted to common on terms specified in subsidiary documents.
Recent MYMD News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 01:04:23 PM
- MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer • Business Wire • 06/17/2024 01:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/31/2024 12:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 01:10:03 PM
- MyMD Pharmaceuticals Secures Strategic Investments • Business Wire • 05/21/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:01:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 04:00:19 PM
- MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • Business Wire • 03/05/2024 02:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:13:35 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 04:27:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:57:03 PM
- MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing • Business Wire • 02/13/2024 04:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 02:15:12 PM
- MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis • Business Wire • 12/06/2023 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/19/2023 01:00:10 PM
- MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain • Business Wire • 10/19/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 09:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 08:30:23 PM
- MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023 • Business Wire • 10/04/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:24:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/24/2023 09:58:33 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM